Interesting TRVN Call Options For November 18th

Investors in Trevena Inc ( TRVN) saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TRVN options chain for the new November 18th contracts and identified the following call contract of particular interest.

The call contract at the $5.00 strike price has a current bid of 10 cents. If an investor was to purchase shares of TRVN stock at the current price level of $4.95/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $5.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 3.03% if the stock gets called away at the November 18th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if TRVN shares really soar, which is why looking at the trailing twelve month trading history for Trevena Inc, as well as studying the business fundamentals becomes important. Below is a chart showing TRVN's trailing twelve month trading history, with the $5.00 strike highlighted in red:

Considering the fact that the $5.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 52%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.02% boost of extra return to the investor, or 92.17% annualized, which we refer to as the YieldBoost.

If you liked this article you might like

3 Beaten-Down Biotechs That Should Head Up

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Endo international, AngioDynamics Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers